Ratings by William Blair (Matt Larew)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 10/6/2026 | Option Care Health | OPCH | Downgrade | Market Perform (Outperform) |
23.37 (31.36) |
34.19% | Details | |
| 10/5/2026 | Revvity Inc | RVTY | New Coverage | Outperform (N/A) |
151.53 (156.01) |
2.96% | Details | |
| 6/26/2026 | Bio-Techne Corp. | TECH | Downgrade | Market Perform (Outperform) |
58.88 (72.58) |
23.27% | Details | |
| 4/1/2026 | Avantor Inc. | AVTR | Maintain | Market Perform (N/A) |
|
Details | ||
| 3/30/2026 | 10X Genomics | TXG | Upgrade | Outperform (Market Perform) |
19.48 (71.46) |
266.84% | Details | |
| 3/23/2026 | MaxCyte Inc. | MXCT | Maintain | Market Perform (N/A) |
|
Details | ||
| 3/3/2026 | 908 Devices Inc. | MASS | Maintain | Outperform (N/A) |
|
Details | ||
| 1/5/2026 | Waters Corp. | WAT | New Coverage | Outperform (N/A) |
381.96 (442.83) |
15.94% | Details | |
| 11/3/2025 | AptarGroup | ATR | Downgrade | Market Perform (Outperform) |
124.36 (125.77) |
1.13% | Details | |
| 10/6/2025 | Charles River Labs | CRL | Upgrade | Outperform (Market Perform) |
177.33 (315.45) |
77.89% | Details | |
| 8/19/2025 | Thermo Fisher Scientific | TMO | New Coverage | Outperform (N/A) |
489.01 (687.37) |
40.56% | Details | |
| 8/7/2025 | MaxCyte Inc. | MXCT | Downgrade | Market Perform (Outperform) |
2.06 (1.43) |
-30.58% | Details | |
| 6/26/2025 | Maravai LifeScience Holdings Inc. | MRVI | Maintain | Market Perform (N/A) |
|
Details | ||
| 12/30/2024 | Amedisys | AMED | Maintain | Market Perform (N/A) |
|
Details | ||
| 11/8/2024 | Maravai LifeScience Holdings Inc. | MRVI | Downgrade | Market Perform (Outperform) |
7.84 (7.20) |
-8.16% | Details | |
| 10/8/2024 | U.S. Physical Therapy | USPH | Maintain | Market Perform (N/A) |
|
Details | ||
| 7/1/2024 | Amedisys | AMED | Downgrade | Market Perform (Outperform) |
92.97 (100.99) |
8.63% | Details | |
| 5/10/2024 | Ginkgo Bioworks Holdings Inc | DNA | Downgrade | Underperform (Market Perform) |
0.92 (9.86) |
971.74% | Details | |
| 4/29/2024 | AptarGroup | ATR | Upgrade | Outperform (Market Perform) |
143.33 (124.36) |
-13.24% | Details | |
| 8/28/2023 | Abcam Plc. | ABCM | Downgrade | Market Perform (Outperform) |
23.36 (23.99) |
2.7% | Details | |
| 8/28/2023 | Bio-Techne Corp. | TECH | New Coverage | Outperform (N/A) |
80.16 (58.88) |
-26.55% | Details | |
| 7/31/2023 | Avantor Inc. | AVTR | Downgrade | Market Perform (Outperform) |
22.83 (16.62) |
-27.2% | Details | |
| 5/11/2023 | Ginkgo Bioworks Holdings Inc | DNA | Downgrade | Market Perform (Outperform) |
1.35 (9.86) |
630.37% | Details | |
| 9/6/2022 | Signify Health Inc | SGFY | Downgrade | Market Perform (Outperform) |
28.77 (30.49) |
5.98% | Details | |
| 3/29/2022 | LHC Group | LHCG | Downgrade | Market Perform (Outperform) |
157.23 (169.81) |
8% | Details | |
| 11/1/2021 | Ginkgo Bioworks Holdings Inc | DNA | Maintain | Outperform (N/A) |
|
Details | ||
| 10/12/2021 | Ginkgo Bioworks Holdings Inc | DNA | New Coverage | Outperform (N/A) |
9.47 (9.86) |
4.12% | Details | |
| 9/22/2021 | Innovage Holding Corp | INNV | Downgrade | Market Perform (Outperform) |
11.65 (9.15) |
-21.46% | Details | |
| 8/4/2021 | Zymergen Inc | ZY | Downgrade | Market Perform (Outperform) |
34.03 (2.43) |
-92.86% | Details | |
| 7/20/2021 | Alpha Teknova Inc. | TKNO | New Coverage | Outperform (N/A) |
18.06 (7.39) |
-59.08% | Details | |
| 6/29/2021 | Twist Bioscience | TWST | New Coverage | Outperform (N/A) |
126.34 (142.70) |
12.95% | Details | |
| 6/29/2021 | Zymergen Inc | ZY | New Coverage | Outperform (N/A) |
39.00 (2.43) |
-93.77% | Details | |
| 3/29/2021 | Innovage Holding Corp | INNV | New Coverage | Outperform (N/A) |
24.35 (9.15) |
-62.42% | Details | |
| 3/8/2021 | Signify Health Inc | SGFY | New Coverage | Outperform (N/A) |
28.31 (30.49) |
7.7% | Details | |
| 12/15/2020 | Maravai LifeScience Holdings Inc. | MRVI | New Coverage | Outperform (N/A) |
25.73 (7.20) |
-72.02% | Details | |
| 3/17/2020 | U.S. Physical Therapy | USPH | Downgrade | Market Perform (Outperform) |
64.46 (87.02) |
35% | Details | |
| 1/31/2020 | U.S. Physical Therapy | USPH | Maintain | Outperform (N/A) |
|
Details | ||
| 9/11/2019 | DaVita | DVA | Downgrade | Market Perform (Outperform) |
61.66 (175.35) |
184.38% | Details | |
| 6/20/2019 | DaVita | DVA | Maintain | Outperform (N/A) |
|
Details | ||
| 3/8/2019 | U.S. Physical Therapy | USPH | New Coverage | Outperform (N/A) |
105.45 (87.02) |
-17.48% | Details |
